Imidazole salicylate in the treatment of osteoarthrosis and musculoskeletal trauma: a postmarketing survey.
A postmarketing survey was conducted by 37 orthopedists and traumatologists among 700 patients of both sexes, aged 7 to 87 years, to evaluate the efficacy and tolerability of imidazole salicylate. The 467 patients with osteoarthrosis received 750-mg tablets (TID) for up to one month and 233 patients with traumatic pathologies received imidazole salicylate gel (BID-TID) for ten days, or tablets (BID-TID), or both gel and tablets combined. The treatment was satisfactory in both patient groups, significantly reducing the intensity of pain and swelling and improving articular function. No adverse experiences that had not been reported previously were recorded; only some gastrointestinal side effects exceeded an incidence of 1%.
Scaricabarozzi
I
I
Italfarmaco S.p.A., Milan, Italy.
Chinea
B
B
Scotti
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000293:injuries*; D002648:Child; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000293:injuries*; D010003:Osteoarthritis / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007093:Imidazoles; D012459:Salicylates; C043292:imidazole-2-hydroxybenzoate